KALA Receives FDA Fast Track Designation for KPI-012, a Human MSC-S Therapy for Persistent Corneal Epithelial Defect 眼科查看全文
發仔说美股2022-12-30 17:30
【美股盘前 | 药品制造商Kala续涨超6%,Wedbush予其47美元目标价】
华盛资讯12月30日消息,美股盘前,三大期指走弱,截至发稿,纳指期货跌0.61%,标普500指数期货跌0.45%,道指期货跌0.32%。
药物制造商Kala Pharmaceuticals盘前上涨6.68%,近两个交易日涨逾317%,Wedbush分析师Andreas Ar...查看全文
一周一次的见面会又来了,还是我→美股风向标。致力于追踪热门美股优质标的,挖掘更多投资机会。接下来我们来看看本周有哪些重要的标的可以关注吧! 1、Kala制药公司 $KALA 表示,FDA接受了其主要候选产品KPI-012——治疗眼睛罕见疾病的研究... 网页链接
智通财经APP获悉,专注于眼部护理的全球医疗专业公司爱尔康(ALC.US)宣布,同意从生物制药公司Kala Pharma(KALA.US)手中收购EYSUVIS(0.25%氯替泼诺混悬滴眼液)和INVELTYS(1%氯替泼诺混悬滴眼液)。 据了解,EYSUVIS是首个也是唯一一个获FD... 网页链接
$Kala制药(KALA)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001558370-20-005533 Act: 34 Size: 204 KB 网页链接
$Kala制药(KALA)$ CT ORDER Confidential treatment order Accession Number: 9999999997-20-002358 Act: 33 Size: 124 KB 网页链接
$Kala制药(KALA)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001558370-20-004560 Act: 34 Size: 346 KB 网页链接
$Kala制药(KALA)$ DEF 14A Other definitive proxy statements Accession Number: 0001558370-20-004558 Act: 34 Size: 1 MB 网页链接
$Kala制药(KALA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001179110-20-004834 Size: 13 KB 网页链接
$Kala制药(KALA)$ 内部交易: 2020-04-09,Chief Medical Officer,Brazzell Romulus K ,期权,67771普通股, $2.99
$Kala制药(KALA)$ 8-K Current report, item 7.01 Accession Number: 0001104659-20-044480 Act: 34 Size: 17 KB 网页链接
$Kala制药(KALA)$ 内部交易: 2020-03-30,Chief Scientific Officer,Chen Hongming ,期权,31000普通股, $2.30
$Kala制药(KALA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001179110-20-004335 Size: 6 KB 网页链接
$Kala制药(KALA)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001193125-20-082611 Act: 34 Size: 149 KB 网页链接